HOME >> BIOLOGY >> NEWS
Vaccine protects against fatal West Nile complication

A vaccine already approved in the United States to prevent a related disease protects experimental animals and may also protect people from the most serious complication associated with West Nile virus infection, say researchers from the University of Texas Medical Branch at Galveston (UTMB).

They report their findings today at the 50th Annual Meeting of the American Society of Tropical Medicine and Hygiene in Atlanta.

Dr. Robert Tesh, a professor in the Center for Tropical Diseases at UTMB and his colleagues tested two vaccines for Japanese encephalitis (JE) for their its ability to protect hamsters from the fatal encephalitis (inflammation of the brain) that is associated with West Nile viral infection.

The JE virus is a flavivirus, a member of the same viral family as the West Nile virus, dengue virus and St. Louis encephalitis virus.

"It looks like the West Nile virus is spreading throughout the Western Hemisphere and it will probably go all the way through the tropics and down to Argentina says Tesh.

In the United States we haven't had much exposure to flaviviruses; but we wanted to see what could happen when the West Nile virus reached an area like Central America where people have already had exposure to other flaviviruses, either through infection or vaccination.

Previous studies in India have suggested that prior infection with the JE virus will protect monkeys from fatal West Nile infections. In this study Tesh and his colleagues first inoculated hamsters with one of three flavivirus vaccines: a live-attenuated JE vaccine currently used on millions of people in China, a killed-virus JE vaccine currently approved for use in the United States and a yellow fever vaccine.

"If we infect hamsters with the New York strain of West Nile virus about half will die of encephalitis if they have not had a previous flavivirus infection," says Tesh. But in the case of the JE-vaccinated hamsters "none of them
'"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
14-Nov-2001


Page: 1 2

Related biology news :

1. Hope Clinic of Emory Vaccine Center receives CDC contract
2. Vaccines against foodborne disease on horizon
3. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
4. Vaccine technique shows potential against common form of lung cancer
5. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
6. Emory Vaccine Research Center study identifies specific gene required for long-term immunity
7. Vaccine prevents stroke in rats
8. Vaccine puts blood-sucking ticks off their food
9. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
10. Vaccine controls AIDS in monkeys, researchers report in Science
11. Vaccine put into tomatoes shows promise fighting virus in lab tests

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vaccine protects against fatal West Nile complication

(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: